THERAPEUTIC DERMATOLOGY

INNOVATION

Continuous innovation is key as we work toward our bold ambition to become the leading dermatology company in the world.

Our R&D teams work relentlessly—with a focus on biotechnologies for injectable and oral products—to help ensure we meet individual consumer and patient needs with superior outcomes.

We have developed a best-in-class pipeline and a track record of first-to-market innovation.  A key priority is advancing the development of nemolizumab, our first-in-class investigational monotherapy for patients with atopic dermatitis, prurigo nodularis and chronic kidney disease-associated pruritus. In Phase III clinical trials, nemolizumab demonstrated significant improvement in both itch and skin lesions. We are actively investigating other indications within and beyond dermatology.

In February 2024, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis and granted Priority Review for the treatment of prurigo nodularis.